Health
Anti-infective therapy for infections caused by drug-resistant gram-negative pathogens now in Phase I study – Outbreak News Today – Outbreak News Today
By NewsDesk @infectiousdiseasenews Biopharmaceutical company, Qpex Biopharma, announced this week the initiation of a Phase…
By NewsDesk @infectiousdiseasenews
Biopharmaceutical company, Qpex Biopharma, announced this week the initiation of a Phase 1 study of QPX9003, a next generation intravenous (IV)-administered synthetic polymyxin for infections caused by drug-resistant…
Continue Reading
-
Business22 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News18 hours agoTips to improve engagement – Proctor
-
Noosa News21 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General16 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline